CN101830852A - Edaravone compound synthesized by new method - Google Patents
Edaravone compound synthesized by new method Download PDFInfo
- Publication number
- CN101830852A CN101830852A CN 201010128317 CN201010128317A CN101830852A CN 101830852 A CN101830852 A CN 101830852A CN 201010128317 CN201010128317 CN 201010128317 CN 201010128317 A CN201010128317 A CN 201010128317A CN 101830852 A CN101830852 A CN 101830852A
- Authority
- CN
- China
- Prior art keywords
- edaravone
- phenylhydrazine
- synthetic method
- reaction
- virahol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention relates to Edaravone synthesized by a new method. The method comprises the following steps of: reacting phenylhydrazine hydrochloride used as initial raw material with sodium hydroxide to generate phenylhydrazine; mixing the phenylhydrazine and ethyl acetoacetate to generate reflux reaction to prepare crude Edaravone; dissolving the crude Edaravone into an isopropanol water solution, adding active carbon for adsorbing and filtering to prepare fine white crystalloid powder. The invention has the advantages of low cost, high product yield and high purity.
Description
Technical field
The present invention relates to a kind of Edaravone compound of variation route, belong to medical technical field.
Background technology
Edaravone, chemical name is: 3-methyl isophthalic acid-phenyl-2-pyrazolin-5-one, molecular formula is: molecular formula: C
10H
10N
2O, molecular weight: 174.20, structural formula is:
Edaravone is a kind of cerebral protective agent (free-radical scavengers).Clinical study prompting N-acetyl Aspartic Acid (NAA) is the sign of specific survival neurocyte, and cerebral infarction their early stage content sharply reduces.Acute period of cerebral infarction the patient give Edaravone, can suppress to block the minimizing of regional cerebral blood flow on every side, makes that NAA content obviously raises than the glycerine control group in the 28th day brain in morbidity back.The preclinical study prompting, rat gives Edaravone at ischemic/ischemia-reperfusion posterior vein, can stop the progress of cerebral edema and cerebral infarction, and alleviates the nervous symptoms of being followed, and suppresses delayed neuronal death.Mechanism research prompting, Edaravone can be removed free radical, suppresses lipid peroxidation, thereby suppresses the oxidative damage of brain cell, vascular endothelial cell, neurocyte.
About the synthetic method of Edaravone, employing phenylhydrazine that report has and the reaction of butanone acid amides make, and the Dante keto-amide is difficult to obtain, and sluggish, and this method is abandoned now substantially; Employing phenylhydrazine that has and methyl aceto acetate at ethanol (referring to US4857542A, synthesize embodiment 1) or water (Dykhanov NN.Ethyl and buty1 acetoacetates, Med Prom SSSR, 1961,15 (1): back flow reaction makes 42-45), the Edaravone purity that this reaction makes is relatively poor, and yield is not high, has only about 70%.
The synthetic method of a kind of yield height, purity height, Edaravone that cost is low becomes the present invention's emphasis of research at present.
Summary of the invention
The object of the present invention is to provide a kind of synthetic method of Edaravone compound of variation route, is starting raw material with the phenylhydrazine hydrochloride, and purity height, yield height, cost are low, has solved the problems referred to above that the preparation Edaravone exists in the prior art.
For achieving the above object, technical scheme of the present invention is as follows:
A kind of synthetic method of Edaravone compound of variation route, synthetic route comprises following process:
Particularly, Edaravone synthetic method of the present invention is characterized in that comprising following synthesis step:
(1) be that the reaction of starting raw material and sodium hydroxide generates phenylhydrazine with the phenylhydrazine hydrochloride;
(2) phenylhydrazine mixes back flow reaction with methyl aceto acetate again, makes the Edaravone crude product.
Above-mentioned described synthesis step, the mol ratio of described phenylhydrazine hydrochloride, sodium hydroxide and methyl aceto acetate are 2～1: 1～2: 1, be preferably 1.04: 1.04: 1.
Above-mentioned described synthesis step, phenylhydrazine mixed back flow reaction 2～4 hours with methyl aceto acetate again, were preferably 2.5 hours.
The synthetic method of above-mentioned described Edaravone also comprises purification step: the Edaravone crude product is dissolved in Virahol-aqueous solution, adds charcoal absorption, filter, make white crystals sprills highly finished product.Wherein the volume ratio of Virahol and water is 1～3: 1 in Virahol-aqueous solution, is preferably 2: 1.
As the present invention's one preferred embodiment, the synthetic method of Edaravone provided by the invention comprises the steps:
(1) is starting raw material with the phenylhydrazine hydrochloride, is added to the water, stirred 0.5 hour, add equimolar sodium hydroxide, stirred 0.5 hour, generate phenylhydrazine;
(2) drip methyl aceto acetate in above-mentioned reaction solution, exothermic heat of reaction was warming up to back flow reaction 2.5 hours, stopped heating, stirred and was as cold as room temperature, filtered, and obtained faint yellow particulate state crude product after the drying;
(3) the adding volume ratio is Virahol-aqueous solution of 2: 1, adds activated carbon, and absorption refluxed 1 hour, and heat filtering is cooled to room temperature and separates out white solid, and filtration drying gets white crystals sprills highly finished product.
Compare with the preparation method of existing Edaravone, the inventive method is that starting raw material replaces phenylhydrazine that production cost is reduced with the phenylhydrazine hydrochloride, present commercially available phenylhydrazine price is 45000 yuan/ton, and the price of phenylhydrazine hydrochloride is 36000 yuan/ton, and make High Purity Phenylhydrazine by adding sodium hydroxide reaction original position and reduced the influence of impurity reaction, by reaction makes the Edaravone crude product with methyl aceto acetate, yield is significantly improved again.Further, the present invention adopts Virahol-aqueous solution to carry out recrystallization, makes the purity of Edaravone significantly improve, and has reached more than 99%.The conventional dehydrated alcohol recrystallization product purity only about 96% that adopts., therefore, use the inventive method to prepare Edaravone, cost reduces, and product yield and purity all significantly improve, and have solved present technological difficulties.
Embodiment
Below further explain and describe content of the present invention by embodiment, but embodiment is not to be construed as limiting the scope of the invention.
Synthesizing of embodiment 1 Edaravone
(1) takes by weighing 13.5g phenylhydrazine hydrochloride (94mmol), join in the 100ml water, stirred 0.5 hour, add equimolar sodium hydroxide 3.76g, stirred 0.5 hour;
(2) drip 11.7g methyl aceto acetate (90mmol) in above-mentioned reaction solution, exothermic heat of reaction was warming up to back flow reaction 2.5 hours, stopped heating, stirred and was as cold as room temperature, filtered, and obtained faint yellow particulate state crude product 15.5g after the drying;
(3) above-mentioned crude product being added the 30ml volume ratio is Virahol-aqueous solution of 2: 1, adds the 2g activated carbon, refluxes 1 hour, and heat filtering is cooled to room temperature and separates out white solid, must white crystals sprills 14.8g, and yield is 90%, mp129 ℃, purity is 99.9%.
Synthesizing of embodiment 2 Edaravones
(1) takes by weighing 15g phenylhydrazine hydrochloride (104mmol), join in the 120ml water, stirred 0.5 hour, add equimolar sodium hydroxide 4.16g, stirred 0.5 hour;
(2) drip 13g methyl aceto acetate (100mmol) in above-mentioned reaction solution, exothermic heat of reaction was warming up to back flow reaction 2.5 hours, stopped heating, stirred and was as cold as room temperature, filtered, and obtained faint yellow particulate state crude product 16.7g after the drying;
(3) above-mentioned crude product being added the 40ml volume ratio is Virahol-aqueous solution of 2: 1, adds the 2.5g activated carbon, refluxes 1 hour, heat filtering is cooled to room temperature and separates out white solid, gets white crystals sprills 16.1g, yield is 88.9%, and mp128 ℃, purity is 99.9%.
Synthesizing of embodiment 3 Edaravones
(1) takes by weighing 22g phenylhydrazine hydrochloride (152mmol), join in the 200ml water, stirred 0.5 hour, add equimolar sodium hydroxide 6.08g, stirred 0.5 hour;
(2) drip 19g methyl aceto acetate (146mmol) in above-mentioned reaction solution, exothermic heat of reaction was warming up to back flow reaction 3 hours, stopped heating, stirred and was as cold as room temperature, filtered, and obtained faint yellow particulate state crude product 24.8g after the drying;
(3) above-mentioned crude product being added the 50ml volume ratio is Virahol-aqueous solution of 2: 1, adds the 3g activated carbon, refluxes 1 hour, and heat filtering is cooled to room temperature and separates out white solid, must white crystals sprills 23.2g, and yield is 87.8%, mp128 ℃, purity is 99.9%.
The comparative example
Methyl aceto acetate 65g (0.5mol) and dehydrated alcohol 180ml are mixed, stir down in 50 ℃ of solution that drip phenylhydrazine 54g (0.5mol) and dehydrated alcohol 30ml composition, dripped Bi Huiliu 2 hours, steam ethanol 60ml, cooling, suction filtration, crystal is with cold absolute ethanol washing 2 times, vacuum-drying gets faint yellow crystallization 70g.Dehydrated alcohol recrystallization 2 times gets yellowish white crystal 5 6g (yield 65%).
Claims (7)
1. the Edaravone compound of a variation route:
2. the synthetic method of Edaravone compound according to claim 1 is characterized in that comprising following synthesis step: (1) is that the reaction of starting raw material and sodium hydroxide generates phenylhydrazine with the phenylhydrazine hydrochloride;
(2) phenylhydrazine mixes back flow reaction with methyl aceto acetate again, makes the Edaravone crude product.
3. the synthetic method of Edaravone according to claim 2, the mol ratio that it is characterized in that described phenylhydrazine hydrochloride, sodium hydroxide and methyl aceto acetate is 2～1: 1～2: 1, be preferably 1.04: 1.04: 1.
4. the synthetic method of Edaravone according to claim 2 is characterized in that phenylhydrazine mixed back flow reaction 2～4 hours with methyl aceto acetate again, was preferably 2.5 hours.
5. according to the synthetic method of each described Edaravone of claim 1～4, it is characterized in that also comprising purification step: the Edaravone crude product is dissolved in Virahol-aqueous solution, adds charcoal absorption, filter, make white crystals sprills highly finished product.
6. the synthetic method of Edaravone according to claim 5 is characterized in that in the purification step that the volume ratio of second Virahol and water is 1～3: 1 in Virahol-aqueous solution, is preferably 2: 1.
7. according to the synthetic method of each described Edaravone of claim 1～6, it is characterized in that comprising the steps:
(1) is starting raw material with the phenylhydrazine hydrochloride, is added to the water, stirred 0.5 hour, add equimolar sodium hydroxide, stirred 0.5 hour, generate phenylhydrazine;
(2) drip methyl aceto acetate in above-mentioned reaction solution, exothermic heat of reaction was warming up to back flow reaction 2.5 hours, stopped heating, stirred and was as cold as room temperature, filtered, and obtained faint yellow particulate state crude product after the drying;
(3) the adding volume ratio is Virahol-aqueous solution of 2: 1, adds activated carbon, and absorption refluxed 1 hour, and heat filtering is cooled to room temperature and separates out white solid, and filtration drying gets white crystals sprills highly finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101283175A CN101830852B (en) | 2010-03-22 | 2010-03-22 | Edaravone compound synthesized by new method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101283175A CN101830852B (en) | 2010-03-22 | 2010-03-22 | Edaravone compound synthesized by new method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101830852A true CN101830852A (en) | 2010-09-15 |
| CN101830852B CN101830852B (en) | 2012-05-09 |
Family
ID=42715091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101283175A Expired - Fee Related CN101830852B (en) | 2010-03-22 | 2010-03-22 | Edaravone compound synthesized by new method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101830852B (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101982463A (en) * | 2010-09-21 | 2011-03-02 | 广西壮族自治区化工研究院 | Method for preparing aryl 5-pyrazolone |
| CN102127020A (en) * | 2010-12-02 | 2011-07-20 | 海南美兰史克制药有限公司 | Edaravone compound and new preparation method thereof |
| CN102285920A (en) * | 2011-09-21 | 2011-12-21 | 湖南科技大学 | Optimal edaravone synthesis method |
| CN102432540A (en) * | 2011-10-11 | 2012-05-02 | 沈阳药科大学 | Novel preparation method and use of bisedaravone and medicinal salts of bisedaravone |
| CN102643234A (en) * | 2012-04-02 | 2012-08-22 | 浙江大学 | Edaravone polymorphic substance and preparation method thereof |
| CN102766097A (en) * | 2012-06-27 | 2012-11-07 | 江苏正大丰海制药有限公司 | Edaravone A-type crystal and preparation method thereof |
| CN103833640A (en) * | 2012-11-16 | 2014-06-04 | 上海医药工业研究院 | Edaravone crystal, preparation method and application thereof |
| CN105753785A (en) * | 2016-03-23 | 2016-07-13 | 海南合瑞制药股份有限公司 | Edaravone compound and preparation method thereof |
| CN105820121A (en) * | 2016-03-26 | 2016-08-03 | 上海大学 | Preparation method of 1-aryl-3-substituent-5-pyrazolone compound |
| CN106117144A (en) * | 2016-06-24 | 2016-11-16 | 合肥久诺医药科技有限公司 | A kind of synthesis technique of high-purity Edaravone |
| CN107216289A (en) * | 2017-06-16 | 2017-09-29 | 江苏天晟药业股份有限公司 | A kind of preparation method of Edaravone |
| CN107501182A (en) * | 2017-07-10 | 2017-12-22 | 中国农业大学 | The trifluoromethyl of 1 substituted-phenyl 5（Difluoromethyl）4 pyrazole carboxylic acid synthetic methods |
| CN108203410A (en) * | 2016-12-20 | 2018-06-26 | 江苏先声药业有限公司 | The synthesis and application of a kind of impurity phenylhydrazine |
| CN112321454A (en) * | 2020-11-25 | 2021-02-05 | 湖南华腾制药有限公司 | Elotriporpa intermediate, preparation method thereof and method for preparing Elotriporpa by using intermediate |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4857542A (en) * | 1985-05-20 | 1989-08-15 | Mitsubishi Chemical Industries Limited | Prophylactic and therapeutic composition for circulatory disorders and method of treatment |
| CN101367763A (en) * | 2007-08-17 | 2009-02-18 | 深圳泛胜塑胶助剂有限公司 | Synthesis process of 1-phenyl-3-methyl-5-pyrazolone |
-
2010
- 2010-03-22 CN CN2010101283175A patent/CN101830852B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4857542A (en) * | 1985-05-20 | 1989-08-15 | Mitsubishi Chemical Industries Limited | Prophylactic and therapeutic composition for circulatory disorders and method of treatment |
| CN101367763A (en) * | 2007-08-17 | 2009-02-18 | 深圳泛胜塑胶助剂有限公司 | Synthesis process of 1-phenyl-3-methyl-5-pyrazolone |
Non-Patent Citations (3)
| Title |
|---|
| 《Tetrahedron》 20090918 Yu-Ying Huang et al Efficient di-bromination of 5-pyrazolones and 5-hydroxypyrazoles by N-bromobenzamide 9592-9597 1-7 , 2 * |
| 《中国药业》 20061231 刘燕华 等 正交设计法选择依达拉奉的合成条件 43－44，第43页"1.2合成反应式"、"1.3操作" 1-7 , 2 * |
| 《染料与染色》 20040430 王树清 等 1-苯基-3-甲基-5-吡唑啉酮的合成工艺研究 114－115，第114页"1.2反应原理"、"1.3实验步骤"，第114页表1 1-7 , 2 * |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101982463A (en) * | 2010-09-21 | 2011-03-02 | 广西壮族自治区化工研究院 | Method for preparing aryl 5-pyrazolone |
| CN102127020A (en) * | 2010-12-02 | 2011-07-20 | 海南美兰史克制药有限公司 | Edaravone compound and new preparation method thereof |
| CN102285920A (en) * | 2011-09-21 | 2011-12-21 | 湖南科技大学 | Optimal edaravone synthesis method |
| CN102285920B (en) * | 2011-09-21 | 2014-07-23 | 湖南科技大学 | Optimal edaravone synthesis method |
| CN102432540A (en) * | 2011-10-11 | 2012-05-02 | 沈阳药科大学 | Novel preparation method and use of bisedaravone and medicinal salts of bisedaravone |
| CN102643234B (en) * | 2012-04-02 | 2015-09-30 | 浙江大学 | Edaravone polymorphic substance and preparation method thereof |
| CN102643234A (en) * | 2012-04-02 | 2012-08-22 | 浙江大学 | Edaravone polymorphic substance and preparation method thereof |
| CN102766097A (en) * | 2012-06-27 | 2012-11-07 | 江苏正大丰海制药有限公司 | Edaravone A-type crystal and preparation method thereof |
| CN102766097B (en) * | 2012-06-27 | 2014-11-05 | 江苏正大丰海制药有限公司 | Edaravone A-type crystal and preparation method thereof |
| CN103833640B (en) * | 2012-11-16 | 2016-06-22 | 国药集团国瑞药业有限公司 | A kind of Edaravone crystal, its preparation method and application thereof |
| CN103833640A (en) * | 2012-11-16 | 2014-06-04 | 上海医药工业研究院 | Edaravone crystal, preparation method and application thereof |
| CN105753785A (en) * | 2016-03-23 | 2016-07-13 | 海南合瑞制药股份有限公司 | Edaravone compound and preparation method thereof |
| CN105753785B (en) * | 2016-03-23 | 2018-03-02 | 海南合瑞制药股份有限公司 | A kind of crystal formation of Edaravone and preparation method thereof |
| CN105820121A (en) * | 2016-03-26 | 2016-08-03 | 上海大学 | Preparation method of 1-aryl-3-substituent-5-pyrazolone compound |
| CN106117144A (en) * | 2016-06-24 | 2016-11-16 | 合肥久诺医药科技有限公司 | A kind of synthesis technique of high-purity Edaravone |
| CN106117144B (en) * | 2016-06-24 | 2019-01-29 | 合肥久诺医药科技有限公司 | A kind of synthesis technology of high-purity Edaravone |
| CN108203410A (en) * | 2016-12-20 | 2018-06-26 | 江苏先声药业有限公司 | The synthesis and application of a kind of impurity phenylhydrazine |
| CN108203410B (en) * | 2016-12-20 | 2022-03-18 | 江苏先声药业有限公司 | Synthesis and application of edaravone impurity |
| CN107216289A (en) * | 2017-06-16 | 2017-09-29 | 江苏天晟药业股份有限公司 | A kind of preparation method of Edaravone |
| CN107501182A (en) * | 2017-07-10 | 2017-12-22 | 中国农业大学 | The trifluoromethyl of 1 substituted-phenyl 5（Difluoromethyl）4 pyrazole carboxylic acid synthetic methods |
| CN112321454A (en) * | 2020-11-25 | 2021-02-05 | 湖南华腾制药有限公司 | Elotriporpa intermediate, preparation method thereof and method for preparing Elotriporpa by using intermediate |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101830852B (en) | 2012-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101830852B (en) | Edaravone compound synthesized by new method | |
| CN102241631A (en) | Method for preparing edaravone raw material | |
| WO2017096772A1 (en) | Method for preparing anti-heart-failure medicine lcz696 | |
| CA2971093A1 (en) | Process of making cenicriviroc and related analogs | |
| CN102060771A (en) | Edaravone crystal form and preparation method thereof | |
| CN102643275A (en) | A new preparation method for Dasatinib N-6 crystal form | |
| CN103833640B (en) | A kind of Edaravone crystal, its preparation method and application thereof | |
| EP2236510B1 (en) | Process for isolation of a mixture of rrrs and sssr configurations of nebivolol intermediates | |
| CN102285920A (en) | Optimal edaravone synthesis method | |
| CN107011322B (en) | Preparation and purification method of dehydrophenylahistine compound | |
| CN107879979A (en) | A kind of preparation method of Dexmedetomidine | |
| KR101258430B1 (en) | Method for producing alpha form crystals of sapropterin hydrochloride | |
| CN101550144B (en) | Preparation technique for mezlocillin | |
| CN106187864A (en) | A kind of method being prepared high-purity bupivacaine alkali by bupivacaine hydrochloride | |
| CN102206185B (en) | Process for refining bendazac lysine and analogs thereof | |
| KR20170060035A (en) | L-proline compound of sodium-glucose cotransporter 2 inhibitor, and monohydrate and crystal of l-proline compound | |
| KR101585189B1 (en) | Process for preparing crystalline form of Sarpogrelate hydrochloride | |
| CN111892527B (en) | Indole derivatives and synthesis method thereof | |
| CN109608398A (en) | A kind of preparation method of Edaravone | |
| CN112028838B (en) | Preparation method of 2-ethoxy-5-fluorouracil impurity | |
| CN104558103B (en) | A kind of preparation method of argatroban intermediate | |
| CN116947832B (en) | Ligustrazine derivative, preparation method and medical application thereof | |
| JPS588065A (en) | Manufacture of ethambutol sulfonic acid derivative | |
| CN102558053B (en) | Synthesis method of fenoldopam mesylate crystal form II | |
| US5516937A (en) | Process for preparing aminoethylglycine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120509 Termination date: 20160322 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |